Before taking Yervoyg(Ipilimumab)

The document highlights the necessity for vigilant monitoring and management of immune-mediated and infusion-related adverse reactions during YERVOY therapy.

Critical Safety Precautions in YERVOY Administration

YERVOY carries a significant risk of severe and potentially fatal immune-mediated adverse reactions, including colitis, hepatitis, endocrinopathies, pneumonitis, nephritis, and dermatologic events. Regular monitoring of clinical chemistries, liver and thyroid function, and patient symptoms is mandatory before each dose. 

Immediate intervention with systemic corticosteroids is recommended for severe reactions, with permanent discontinuation in life-threatening cases. Infusion-related reactions require prompt management, including interruption or cessation of therapy. Special caution is advised in patients with prior allogeneic hematopoietic stem cell transplantation.